Gadoteridol
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Gadoteridol
Gadoteridol: Known uses and market status in Canada
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Gadoteridol, so there is currently no new predicted indication. The drug’s recorded uses are listed below; no known uses are recorded for this drug.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 0 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02229056 | PROHANCE | Valid |
Safety Considerations
- Drug Interactions: 19 interactions were identified, all rated Moderate. All involve beta-blockers: acebutolol, atenolol, betaxolol (systemic and ophthalmic), bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, sotalol, timolol (systemic and ophthalmic), carteolol (ophthalmic), levobunolol (ophthalmic) and metipranolol (ophthalmic).
Please refer to the package insert for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.